OncLive TV

Meletios A. Dimopoulos, MD, discusses patient-reported outcomes with BPd in pretreated patients with relapsed/refractory multiple myeloma.

Terence W. Friedlander, MD, discusses the design and methodology of the Duravelo-2 study of zelenectide pevedotin in advanced/metastatic urothelial cancer.

Sandra Mazzoni, DO, discusses the emerging role of quadruplet regimens in newly diagnosed multiple myeloma.

Binod Dhakal, MD, discusses the design of the CARTITUDE-4 study investigating cilta-cel in relapsed/refractory multiple myeloma.

Jorge E. Cortes, MD, discusses efficacy and safety findings from the phase 4 BYOND study in previously treated patients with Ph+ chronic myeloid leukemia.

Nicolas Girard, MD, discusses finding from the LUMINOSITY trial in c-Met protein–overexpressing, EGFR wild-type, non–small cell lung cancer.

Sunil Adige, MD, discusses aspects of post-treatment care that can improve long-term quality of life and reduce the risk of breast cancer recurrence.

Minoo Battiwalla, MD, MS, discusses the potential of FLT3-ITD and menin inhibitors to broaden the acute myeloid leukemia treatment paradigm.

Samuel J. Klempner, MD, discusses the FDA approval of zolbetuximab for CLDN18.2+, HER2–, locally advanced unresectable or metastatic gastric/GEJ adenocarcinoma.

Jill Corre, PharmD, PhD, discusses the implications of using daratumumab plus bortezomib, thalidomide, and dexamethasone in newly diagnosed myeloma.

Chad Tang, MD, discusses unanswered questions surrounding the role of radiation therapy in renal cell carcinoma.

Grzegorz S. Nowakowski, MD, discusses the potential implications of the TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with PCNSL.

Leo I. Gordon, MD, discusses future steps for optimizing the use of lisocabtagene maraleucel in the treatment of relapsed/refractory mantle cell lymphoma.

Terence W. Friedlander, MD, discusses emerging agents of interest in urothelial carcinoma.

Grzegorz S. Nowakowski, MD, discusses the clinical implications of the FDA approval of third-line epcoritamab for relapsed/refractory follicular lymphoma.

Jill Corre, PharmD, PhD, discusses the CASSIOPEIA trial of daratumumab plus bortezomib, thalidomide, and dexamethasone in newly diagnosed myeloma.

Idoroenyi Amanam, MD, discusses the JAK inhibitors he most commonly reaches for in his clinical practice when treating patients with myelofibrosis.

Joseph M. Scandura, MD, PhD, discusses the phase 2 SENTRY-2 study evaluating single-agent selinexor in JAK inhibitor–naive myelofibrosis.

Rebecca Klisovic, MD, discusses 3 case studies about patients with myelofibrosis.

Domenica Lorusso, MD, PhD, discusses the selective glucocorticoid receptor modulator relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Nancy U. Lin, MD, discusses the importance of the DESTINY-Breast12 trial of T-DXd in patients with HER2+ breast cancer with vs without brain metastases.

John K. Lee, MD, PhD, discusses the significance of the tumor-agnostic approval of T-DXd specifically for patients with HER2-positive urothelial cancer.

David Sallman, MD, discusses the clinical implications of the 2023 FDA approval of luspatercept for patients with very low– to intermediate-risk MDS.

Oleg Gluz, MD, discusses the rationale for investigating neoadjuvant endocrine therapy plus trastuzumab and pertuzumab in HR+/HER2+ early breast cancer.

Benjamin Adam Weinberg, MD, discusses the ability of ctDNA-based MRD detection to predict the benefit of adjuvant chemotherapy in resected CRC.

Yungan Tao, MD, discusses the efficacy of avelumab plus cetuximab and radiotherapy in patients with head and neck squamous cell carcinoma.

Jared Weiss, MD, discusses outcomes with first-line Versamune HPV plus pembrolizumab in HPV16–positive recurrent or metastatic HNSCC.

Guru P. Sonpavde, MD, discusses topline data from an exploratory analysis of CheckMate 901 in metastatic urothelial cancer.

Martin H. Voss, MD, discusses the clinical significance of the phase 3 KEYNOTE-564 trial in clear cell renal cell carcinoma.

Sally Lau, MD, discusses the addition of tarlatamab to a PD-L1 inhibitor as first-line maintenance therapy for extensive-stage small cell lung cancer.